Mark A Marzinke1, Autumn Breaud2, Teresa L Parsons3, Myron S Cohen4, Estelle Piwowar-Manning2, Susan H Eshleman2, William Clarke5. 1. Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Medicine, the Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2. Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3. Department of Medicine, the Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4. Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. 5. Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: wclarke@jhmi.edu.
Abstract
BACKGROUND: Antiretroviral drugs are used for the treatment and prevention of HIV infection. Non-adherence to antiretroviral drug regimens can compromise their clinical efficacy and lead to emergence of drug-resistant HIV. Clinical trials evaluating antiretroviral regimens for HIV treatment and prevention can also be compromised by poor adherence and non-disclosed off-study antiretroviral drug use. This report describes the development and validation of a high throughput, qualitative method for the identification of antiretroviral drugs using high-resolution mass spectrometry (HRMS) for the retrospective assessment of off-study antiretroviral drug use and the determination of potential antiretroviral therapy (ART) non-compliance. METHODS: Serum standards were prepared that contained 15 antiretroviral drugs: 9 protease inhibitors (PIs), 4 nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), and 2 non-nucleoside/nucleotide reverse transcriptase inhibitors (NNRTIs). Analytical separation was achieved on a Hypersil Gold PFP (100×3mm) column and the eluent was analyzed using the Thermo Exactive Orbitrap mass spectrometer (Exactive-MS) operated in full scan mode. Limit of identification, signal intensity precision, retention time analysis, selectivity, and carryover studies were conducted. Concordance with liquid chromatographic-tandem mass spectrometric (LC-MS/MS) methods was evaluated using remnant plasma samples from a clinical trial. RESULTS: The limit of identification ranged from 5 to 10ng/ml for 14 drugs (9 PIs, 1 NNRTI, 4 NRTIs) and was 150ng/ml for 1 NNRTI. Precision studies with high and low control mixtures revealed signal intensity coefficients of variation of 3.0-27.5%. The Exactive-MS method was selective for the compounds of interest. Overall, concordance ranged from 89.1% to 100% for the screening of antiretroviral drugs in clinical plasma specimens as compared to LC-MS/MS methods. CONCLUSION: Using the Exactive-MS, we developed and validated a highly selective, robust method for the multiplexed detection of 15 antiretroviral drugs.
BACKGROUND: Antiretroviral drugs are used for the treatment and prevention of HIV infection. Non-adherence to antiretroviral drug regimens can compromise their clinical efficacy and lead to emergence of drug-resistant HIV. Clinical trials evaluating antiretroviral regimens for HIV treatment and prevention can also be compromised by poor adherence and non-disclosed off-study antiretroviral drug use. This report describes the development and validation of a high throughput, qualitative method for the identification of antiretroviral drugs using high-resolution mass spectrometry (HRMS) for the retrospective assessment of off-study antiretroviral drug use and the determination of potential antiretroviral therapy (ART) non-compliance. METHODS: Serum standards were prepared that contained 15 antiretroviral drugs: 9 protease inhibitors (PIs), 4 nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs), and 2 non-nucleoside/nucleotide reverse transcriptase inhibitors (NNRTIs). Analytical separation was achieved on a Hypersil Gold PFP (100×3mm) column and the eluent was analyzed using the Thermo Exactive Orbitrap mass spectrometer (Exactive-MS) operated in full scan mode. Limit of identification, signal intensity precision, retention time analysis, selectivity, and carryover studies were conducted. Concordance with liquid chromatographic-tandem mass spectrometric (LC-MS/MS) methods was evaluated using remnant plasma samples from a clinical trial. RESULTS: The limit of identification ranged from 5 to 10ng/ml for 14 drugs (9 PIs, 1 NNRTI, 4 NRTIs) and was 150ng/ml for 1 NNRTI. Precision studies with high and low control mixtures revealed signal intensity coefficients of variation of 3.0-27.5%. The Exactive-MS method was selective for the compounds of interest. Overall, concordance ranged from 89.1% to 100% for the screening of antiretroviral drugs in clinical plasma specimens as compared to LC-MS/MS methods. CONCLUSION: Using the Exactive-MS, we developed and validated a highly selective, robust method for the multiplexed detection of 15 antiretroviral drugs.
Authors: Qizhi Hu; Robert J Noll; Hongyan Li; Alexander Makarov; Mark Hardman; R Graham Cooks Journal: J Mass Spectrom Date: 2005-04 Impact factor: 1.982
Authors: Jessica M Fogel; Lei Wang; Teresa L Parsons; San-San Ou; Estelle Piwowar-Manning; Ying Chen; Victor O Mudhune; Mina C Hosseinipour; Johnstone Kumwenda; James G Hakim; Suwat Chariyalertsak; Ravindre Panchia; Ian Sanne; Nagalingeswaran Kumarasamy; Beatriz Grinsztejn; Joseph Makhema; Jose Pilotto; Breno R Santos; Kenneth H Mayer; Marybeth McCauley; Theresa Gamble; Namandjé N Bumpus; Craig W Hendrix; Myron S Cohen; Susan H Eshleman Journal: J Infect Dis Date: 2013-08-01 Impact factor: 5.226
Authors: Jessica M Fogel; Estelle Piwowar-Manning; Kelsey Donohue; Vanessa Cummings; Mark A Marzinke; William Clarke; Autumn Breaud; Agnès Fiamma; Deborah Donnell; Michal Kulich; Jessie K K Mbwambo; Linda Richter; Glenda Gray; Michael Sweat; Thomas J Coates; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2015-08-01 Impact factor: 3.731
Authors: Sarah Pollock; Forrest Toegel; August F Holtyn; Andrew M Rodewald; Jeannie-Marie Leoutsakos; Michael Fingerhood; Kenneth Silverman Journal: Drug Alcohol Depend Date: 2020-04-25 Impact factor: 4.492
Authors: Forrest Toegel; August F Holtyn; Sarah Pollock; Andrew M Rodewald; Jeannie-Marie Leoutsakos; Michael Fingerhood; Kenneth Silverman Journal: HIV Res Clin Pract Date: 2020-03-05
Authors: Iris Chen; Vanessa Cummings; Jessica M Fogel; Mark A Marzinke; William Clarke; Matthew B Connor; Sam Griffith; Susan Buchbinder; Steven Shoptaw; Carlos Del Rio; Manya Magnus; Sharon Mannheimer; Darrell P Wheeler; Kenneth H Mayer; Beryl A Koblin; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2014-12-01 Impact factor: 3.731
Authors: Yinfeng Zhang; Mariya V Sivay; Sarah E Hudelson; William Clarke; Autumn Breaud; Jing Wang; Estelle Piwowar-Manning; Yaw Agyei; Jessica M Fogel; Erica L Hamilton; Amanda Selin; Catherine MacPhail; Kathleen Kahn; Francesc Xavier Gómez-Olivé; James P Hughes; Audrey Pettifor; Susan H Eshleman Journal: J Acquir Immune Defic Syndr Date: 2018-11-01 Impact factor: 3.731
Authors: Jessica M Fogel; Yinfeng Zhang; Philip J Palumbo; Xu Guo; William Clarke; Autumn Breaud; Paul Richardson; Estelle Piwowar-Manning; Erica L Hamilton; Tran Viet Ha; Kostyantyn Dumchev; Zubairi Djoerban; Irving Hoffman; Brett Hanscom; William C Miller; Susan H Eshleman Journal: AIDS Behav Date: 2019-08
Authors: Yinfeng Zhang; William Clarke; Mark A Marzinke; Estelle Piwowar-Manning; Geetha Beauchamp; Autumn Breaud; Craig W Hendrix; Gavin A Cloherty; Lynda Emel; Scott Rose; Lisa Hightow-Weidman; Marc Siegel; Steven Shoptaw; Sheldon D Fields; Darrell Wheeler; Susan H Eshleman Journal: Antimicrob Agents Chemother Date: 2017-06-27 Impact factor: 5.191
Authors: Gabor D Kelen; Yu-Hsiang Hsieh; Richard E Rothman; Eshan U Patel; Oliver B Laeyendecker; Mark A Marzinke; William Clarke; Teresa Parsons; Jordyn L Manucci; Thomas C Quinn Journal: AIDS Date: 2016-01-02 Impact factor: 4.177